NCT04525105

Brief Summary

Urge urinary incontinence (UUI) is a common health problem. Changes in collagen metabolism in pelvic support organs, such as uterosacral ligaments (USLs), might be responsible for the complex pathophysiology of UUI. The TGF-β pathway is involved in collagen synthesis and degradation. The Transforming Growth Family- β (TGF-β) superfamily has essential intracellular signaling components, such as newly identified SMAD family members. We evaluated the changes in the levels of TGF-β and SMAD gene and protein expression in the USL of patients with concomitant pelvic organ prolapse (POP) and UUI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2017

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 20, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 25, 2020

Completed
Last Updated

August 25, 2020

Status Verified

August 1, 2020

Enrollment Period

2.2 years

First QC Date

August 20, 2020

Last Update Submit

August 20, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • SMAD2

    tissue expression and protein level

    intraoperative

  • SMAD3

    tissue expression and protein level

    intraoperative

  • TGF-ß1 mRNA Expression Levels

    tissue expression and protein level

    intraoperative

Study Arms (2)

Study group

wıth URGE INCONTINANCE

Genetic: SMAD2

Control group

not urge incontinance

Genetic: SMAD2

Interventions

SMAD2GENETIC

a family of structurally related cytokines

Also known as: SMAD3, TGF-β1
Control groupStudy group

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility Details\> 18 years
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients who had been diagnosed with POP and UUI and asymptomatic women without complaints of POP and UUI

You may qualify if:

  • patients who had been diagnosed with POP and UUI
  • asymptomatic women without complaints of POP and UUI

You may not qualify if:

  • Women who have SUI,
  • a history of gynecologic malignancy,
  • endometriosis,
  • connective tissue disorders,
  • asthma,
  • previous pelvic inflammatory disease,
  • pelvic radiation anamnesis,
  • smoking,
  • previous surgery for POP or UI,
  • those on steroid therapy and hormone replacement therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mugla Sıtkı Kocman University Faculty of Medicine

Muğla, 48000, Turkey (Türkiye)

Location

Related Publications (1)

  • Akin MN, Sivaslioglu AA, Edgunlu T, Kasap B, Celik SK. SMAD2, SMAD3 and TGF-beta GENE expressions in women suffering from urge urinary incontinence and pelvic organ prolapse. Mol Biol Rep. 2021 Feb;48(2):1401-1407. doi: 10.1007/s11033-021-06220-4. Epub 2021 Feb 18.

MeSH Terms

Conditions

Pelvic Organ ProlapseUrinary Incontinence, Urge

Condition Hierarchy (Ancestors)

ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsUrinary IncontinenceUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Melike Nur Akın

Study Record Dates

First Submitted

August 20, 2020

First Posted

August 25, 2020

Study Start

November 1, 2017

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

August 25, 2020

Record last verified: 2020-08

Locations